{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T21:07:44Z","timestamp":1784408864772,"version":"3.55.0"},"reference-count":20,"publisher":"Japanese Society of Internal Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026]]},"DOI":"10.2169\/internalmedicine.7653-26","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:12:45Z","timestamp":1782511965000},"source":"Crossref","is-referenced-by-count":1,"title":["A Possible Case of Drug-induced ANCA-associated Vasculitis Associated with Mirabegron"],"prefix":"10.2169","author":[{"given":"Yumi","family":"Kawamoto","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Shin-Koga Hospital"},{"name":"Department of Medicine, Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinjiro","family":"Kaieda","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Hasuo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shin-Koga Hospital"},{"name":"Department of Medicine, Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. Nat Rev Rheumatol 10: 463-473, 2014.","DOI":"10.1038\/nrrheum.2014.103"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kessenbrock K, Krumbholz M, Schonermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 15: 623-625, 2009.","DOI":"10.1038\/nm.1959"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Xiao H, Dairaghi DJ, Powers JP, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 25: 225-231, 2014.","DOI":"10.1681\/ASN.2013020143"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Nakazawa D, Tomaru U, Ishizu A. Possible implication of disordered neutrophil extracellular traps in the pathogenesis of MPO-ANCA-associated vasculitis. Clin Exp Nephrol 17: 631-633, 2013.","DOI":"10.1007\/s10157-012-0738-8"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Cohen Tervaert JW. Drug- and vaccine induced ANCA-associated vasculitis: An overview. Autoimmun Rev 25: 103924, 2026.","DOI":"10.1016\/j.autrev.2025.103924"},{"key":"6","unstructured":"6. Radic M, Martinovic Kaliterna D, Radic J. Drug-induced vasculitis: a clinical and pathological review. Neth J Med 70: 12-17, 2012."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Choi HK, Merkel PA, Walker AM, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 43: 405-413, 2000.","DOI":"10.1002\/1529-0131(200002)43:2<405::AID-ANR22>3.0.CO;2-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Weng CH, Liu ZC. Drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Chin Med J (Engl) 132: 2848-2855, 2019.","DOI":"10.1097\/CM9.0000000000000539"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Deshayes S, Dolladille C, Dumont A, et al. A Worldwide Pharmacoepidemiologic Update on Drug-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the Era of Targeted Therapies. Arthritis Rheumatol 74: 134-139, 2022.","DOI":"10.1002\/art.41902"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66: 222-227, 2007.","DOI":"10.1136\/ard.2006.054593"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Wang J, Zhang A, Ye M, Zhang C. Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database. Front Pharmacol 15: 1376535, 2024.","DOI":"10.3389\/fphar.2024.1376535"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. van Timmeren MM, Heeringa P. Pathogenesis of ANCA-associated vasculitis: recent insights from animal models. Curr Opin Rheumatol 24: 8-14, 2012.","DOI":"10.1097\/BOR.0b013e32834bde57"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Hartung JE, Ciszek BP, Nackley AG. beta2- and beta3-adrenergic receptors drive COMT-dependent pain by increasing production of nitric oxide and cytokines. Pain 155: 1346-1355, 2014.","DOI":"10.1016\/j.pain.2014.04.011"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 356: 1255-1259, 2000.","DOI":"10.1016\/S0140-6736(00)02799-9"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. Nat Rev Dis Primers 6: 71, 2020.","DOI":"10.1038\/s41572-020-0204-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Gao Y, Chen M, Ye H, Yu F, Guo XH, Zhao MH. Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. Rheumatology (Oxford) 47: 1515-1520, 2008.","DOI":"10.1093\/rheumatology\/ken321"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hogan SL, Nachman PH, Poulton CJ, et al. Understanding Long-term Remission Off Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Kidney Int Rep 4: 551-560, 2019.","DOI":"10.1016\/j.ekir.2019.01.004"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Watanabe H, Sada KE, Matsumoto Y, et al. Association Between Reappearance of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Subgroup Analysis of Nationwide Prospective Cohort Studies. Arthritis Rheumatol 70: 1626-1633, 2018.","DOI":"10.1002\/art.40538"},{"key":"19","unstructured":"19. Chen YX, Yu HJ, Ni LY, et al. Propylthiouracil-associated antineutrophil cytoplasmic autoantibody-positive vasculitis: retrospective study of 19 cases. J Rheumatol 34: 2451-2456, 2007."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Ishii R, Imaizumi M, Ide A, et al. A long-term follow-up of serum myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves disease treated with propylthiouracil. Endocr J 57: 73-79, 2010.","DOI":"10.1507\/endocrj.K09E-230"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7653-26\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T03:27:04Z","timestamp":1782530824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/advpub\/0\/advpub_7653-26\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":20,"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.7653-26","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"7653-26"}}